Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 30, 2012

Arabio Appoints Alphamed as Vaccines Distributor in UAE

  • Saudi Arabia-based Arabio appointed Alphamed as its sales and distribution partner in the United Arab Emirates (UAE). Arabio claims to be the only Arab firm specialized in producing biologics and vaccines, and started manufacturing operations at its 10,000 m2 facility in Makkah, in August 2011.  

    Arabio has a technology transfer agreement in place with Novartis Vaccines & Diagnostics, which will enable the manufacture of all the latter’s vaccines at the Makkah facility. Production has already started for Novartis’ Menveo meningitis vaccine, Agrippal flu vaccine, and Quinvaxem, a pentavalent vaccine developed with Crucell against whooping cough, diphtheria, tetanus, hemophilus influenza type B, and hepatitis B.

    Arabio says it aims to export its products to the Gulf region as well as to Yemen, Iraq, Jordan, Lebanon, Palestine, Syria, Sudan, Egypt, Libya, Algeria, Tunisia, Morocco, and Mauritania. The firm has additional rights to export to some African and other Islamic countries. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »